Full Text View
Tabular View
No Study Results Posted
Related Studies
11C Topotecan PET Imaging
This study has been terminated.
( Drugs unavailable:unable to make radioactive topotecan )
Study NCT00253461   Information provided by Case Comprehensive Cancer Center

First Received on November 11, 2005.   Last Updated on March 16, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lung Cancer
Metastatic Cancer
Ovarian Cancer
Additional conditions recognized in this trial
Lung Neoplasms
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Lung Diseases
Neoplasms by Site
Neoplastic Processes
Ovarian Diseases
Pathologic Processes
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Urogenital Neoplasms
Interventions listed in this trial
computed tomography
positron emission tomography
11C topotecan
fludeoxyglucose F 18
Additional drug interventions recognized in this trial
Topotecan
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Sponsors listed in this trial
Case Comprehensive Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services